Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 6/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259373 | 1.00 | CTSL (0.44) | CTSLCTSBCTSKDPP4KDM1A | |
| SCHEMBL31614154 | 1.00 | CTSL (0.44) | CTSLCTSBCTSKDPP4KDM1A | |
| SCHEMBL31200884 | 1.00 | CTSL (0.44) | CTSLCTSBCTSKDPP4KDM1A | |
| Hydrochloric Acid SCHEMBL31614129 | 0.98 | CTSL (0.43) | CTSLCTSBCTSKDPP4KDM1A | |
| SCHEMBL741693 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKDPP4KDM1A | |
| SCHEMBL741694 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKDPP4KDM1A | |
| SCHEMBL15259415 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKDPP4KDM1A | |
| SCHEMBL741692 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKDPP4KDM1A | |
| SCHEMBL2413107 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKDPP4NAAA | |
| SCHEMBL743123 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKDPP4NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | CTSL 678/4885CTSB 1063/4885CTSK 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.